This is the online version of ASH in 30 Seconds, STAT’s report from the American Society of Hematology meeting. Sign up for the email version here.
It’s Day 2 of the ASH meeting. Let’s get straight into the news.
Fulcrum study suggests improved efficacy for higher dose sickle cell pill
Fulcrum Therapeutics said Sunday that a higher dose of its experimental pill for sickle cell disease was more effective at inducing an alternative form of the oxygen-carrying molecule hemoglobin — boosting hopes it could one day provide a simple and effective treatment for the disease.
